Genetics on the Big Screen



By Bio-IT World Staff

January 22, 2010 | “Extraordinary Measures,” starring Harrison Ford and Brendan Fraser, is a film based on Wall Street Journal reporter Geeta Anand's book "The Cure: How a Father Raised $100 Million—and Bucked the Medical Establishment—in a Quest to Save His Children." It is inspired by the story of John Crowley (Brendan Fraser), a father of two children affected by Pompe disease. In the late 1990s Crowley joined with a researcher named William Canfield (Robert Stonehill) to try and develop a treatment for Pompe.

Pompe disease is a rare disorder that affects only about 10,000 patients worldwide.  In patients with Pompe, an enzyme known as acid alpha-glucosidase (GAA) is either missing or in short supply.  GAA is responsible for the breakdown of glycogen, a form of sugar stored in muscle cells throughout the body.  In patients with Pompe, glycogen builds up in cells in the body, weakening and damaging muscles.  As it progresses, Pompe can cause a range of serious health problems and can affect breathing and mobility.

Myozyme, the first and only FDA-approved product to treat Pompe disease, was developed by Genzyme Corporation. In the movie, the "Special Medicine," is Myozyme and it was developed based on research conducted by Genzyme in collaboration with researchers at Duke University and the Erasmus Medical Center in The Netherlands.  The drug candidate originally developed by Crowley and Canfield failed to achieve data statistically significant to continue development.

The clinical research program to develop Myozyme was a monumental and historic event in medical history.  The development effort included 2 global clinical research studies conducted at 7 study sites over 3 years.  These were some of the first clinical trials ever conducted involving Pompe patients, and John Crowley's children, Megan and Patrick, were some of the first patients treated with Myozyme.

Genzyme has posted a link on their website, which includes the “real story” behind Myozyme with videos of some of the scientists and patients: http://www.genzyme.com/pompemovie/. The Wall Street Journal’s Review Revue here.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 
Apply at http://jobs.tessella.com   

oxford nanopore logo 


Early Access Collaborations ManagersClick here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Click to  Apply  

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .